A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience
This methodological paper (2016) outlines the development of a target-controlled intravenous infusion protocol for administering DMT within the context of neuroimaging research. Whereas a single dose does not exert effects beyond 20 minutes, this method maintains a stable brain concentration that enables the investigation of a stable and prolonged DMT experience over an indefinite period.
Authors
- Rick Strassman
Published
Abstract
Introduction
The state of consciousness induced by N,N-dimethyltryptamine (DMT) is one of the most extraordinary of any naturally-occurring psychedelic substance. Users consistently report the complete replacement of normal subjective experience with a novel “alternate universe,” often densely populated with a variety of strange objects and other highly complex visual content, including what appear to be sentient “beings.” The phenomenology of the DMT state is of great interest to psychology and calls for rigorous academic enquiry. The extremely short duration of DMT effects-less than 20 min-militates against single dose administration as the ideal model for such enquiry.
Methods
Using pharmacokinetic modeling and DMT blood sampling data, we demonstrate that the unique pharmacological characteristics of DMT, which also include a rapid onset and lack of acute tolerance to its subjective effects, make it amenable to administration by target-controlled intravenous infusion.
Results
This is a technology developed to maintain a stable brain concentration of anesthetic drugs during surgery.
Discussion
Simulations of our model demonstrate that this approach will allow research subjects to be induced into a stable and prolonged DMT experience, making it possible to carefully observe its psychological contents, and provide more extensive accounts for subsequent analyses. This model would also be valuable in performing functional neuroimaging, where subjects are required to remain under the influence of the drug for extended periods. Finally, target-controlled intravenous infusion of DMT may aid the development of unique psychotherapeutic applications of this psychedelic agent.
Research Summary of 'A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience'
Introduction
N,N-dimethyltryptamine (DMT) produces rapid, profound and highly reproducible alterations of consciousness, commonly described as the replacement of ordinary awareness by an ‘‘alternate universe’’ populated by complex visual objects and apparent sentient ‘‘beings.’’ The compound is endogenously produced in humans, crosses the blood–brain barrier in animals, and is metabolised rapidly by monoamine oxidase (MAO) enzymes; these pharmacological features, together with the striking phenomenology, make DMT of considerable interest for psychology and neuroscience. Despite this, detailed phenomenological characterisation has been limited in part because the effects of inhaled or intravenous bolus DMT are very brief, typically resolving within 20–30 min, which hampers prolonged observation and functional neuroimaging during the state. Gallimore and Strassman set out to determine whether target-controlled intravenous infusion—a methodology from anaesthesia used to achieve and maintain a stable brain concentration of drug—could be applied to DMT. Using time-series plasma DMT data from prior human dosing sessions, the investigators developed and simulated pharmacokinetic (PK) and effect-site models to test whether a controlled infusion protocol could produce a sustained, stable DMT effect-site concentration, and to derive candidate infusion parameters for research use.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Pro members can view the original manuscript directly in the browser.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- Author
- APA Citation
Gallimore, A. R., & Strassman, R. J. (2016). A Model for the Application of Target-Controlled Intravenous Infusion for a Prolonged Immersive DMT Psychedelic Experience. Frontiers in Pharmacology, 7. https://doi.org/10.3389/fphar.2016.00211
References (23)
Papers cited by this study that are also in Blossom
Barker, S., McIlhenny, E. H., Strassman, R. J. · Drug Testing and Analysis (2012)
Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Buchborn, T., Schröder, H., Höllt, V. et al. · Journal of Psychopharmacology (2014)
Callaway, J. C., Mckenna, D. J., Grob, C. S. et al. · Journal of Ethnopharmacology (1999)
Carhart-Harris, R. L., Erritzoe, D., Williams, T. et al. · PNAS (2012)
Carhart-Harris, R. L., Muthukumaraswamy, S., Roseman, L. et al. · PNAS (2016)
Gallimore, A. R. · Frontiers in Human Neuroscience (2015)
Gouzoulis-Mayfrank, E., Heekeren, K., Neukirch, A. et al. · Pharmacopsychiatry (2005)
Grob, C. S., Danforth, A. L., Chopra, G. S. et al. · JAMA Psychiatry (2011)
Show all 23 referencesShow fewer
Grof, S., Goodman, L. E., Richards, W. A. · Pharmacopsychiatry (1973)
Hendricks, P. S., Clark, B., Johnson, M. W. et al. · Journal of Psychopharmacology (2014)
Krebs, T. S., Johansen, P. Ø. · Journal of Psychopharmacology (2012)
Mangini, M. · Journal of Psychoactive Drugs (2011)
McKenna, D., Towers, G. H., Abbott, F. · Journal of Ethnopharmacology (1984)
Nichols, D. E. · Pharmacological Reviews (2016)
Riba, J., Urbano, G., Morte, A. et al. · Psychopharmacology (2001)
Roseman, L., Leech, R., Feilding, A. et al. · Frontiers in Human Neuroscience (2014)
Speth, J., Speth, C., Kaelen, M. et al. · Journal of Psychopharmacology (2016)
Strassman, R. J., Qualls, C .R. · JAMA Psychiatry (1994)
Strassman, R. J., Qualls, C. R., Berg, L. M. · Biological Psychiatry (1996)
Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H. et al. · JAMA Psychiatry (1994)
Vollenweider, F. X., Leenders, K. L., Maguire, P. et al. · Neuropsychopharmacology (1997)
Cited By (11)
Papers in Blossom that reference this study
Witowski, C. G., Hess, M. R., Jones, N. T. et al. · European Journal of Pharmacology (2024)
Luan, L. X., Eckernäs, E., Ashton, M. et al. · Journal of Psychopharmacology (2023)
Eckernäs, E., Koomen, J., Timmermann, |. C. et al. · Pharmacometrics and Systems Pharmacology (2023)
Reckweg, J., van Leeuwen, C., Theunissen, E. L. et al. · Frontiers in Psychiatry (2023)
Michael, P., Luke, D., Robinson, O. · Frontiers in Psychology (2023)
Eckernäs, E., Timmermann, C., Carhart-Harris, R. et al. · Clinical and Translational Science (2022)
Aday, J. S., Davoli, C. C., Bloesch, E. K. · Therapeutic Advances in Psychopharmacology (2020)
Barker, S. · Frontiers in Neuroscience (2018)
Walsh, Z., Bird, B. M., Lafrance, A. et al. · Journal of Psychopharmacology (2018)
Nichols, D. E. · Journal of Psychopharmacology (2017)
Show all 11 papersShow fewer
Dolder, P. C., Schmid, Y., Steuer, A. E. et al. · Clinical Pharmacokinetics (2017)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.